PharmaCyte Biotech, Inc. (PMCB) Dividend History

PharmaCyte Biotech, Inc. is a biotechnology company focused on developing cell therapy-based treatments for cancer and other serious diseases. The company leverages its proprietary live-cell encapsulation platform to create therapies that deliver targeted and sustained drug release, aiming to improve patient outcomes.

23046 Avenida De La Carlota, Suite 600, Laguna Hills, CA, 92653
Phone: (917) 595.2850
Website: https://pharmacyte.com

Dividend History

PharmaCyte Biotech, Inc. currently does not pay dividends

Company News

  • The pancreatic cancer treatment market is expected to grow significantly, driven by the increasing prevalence of the disease and the development of innovative therapies. Factors like the rising geriatric population, emerging chemotherapies, and increased healthcare investments in Asia-Pacific and the Middle East are further propelling the market growth.

    GlobeNewswire Inc.
    Featured Companies: AMGN BMY MRK PFE
  • Meta Platforms, Inc. announced a whopping $40 billion share repurchase program.

    Seeking Alpha
    Featured Companies: AAPL ARW META ON PINS SWKS VRTX
  • Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (NASDAQ: ADGI) (IPOed Aug. 6) Alkermes plc (NASDAQ: ALKS) Bio-Rad Laboratories, Inc. (NYSE: BIO) Candel Therapeutics, Inc. (NASDAQ: CADL) (IPOed July 26) Century Therapeutics, Inc. (NASDAQ: IPSC) (reacted to its second-quarter results) Dynavax Technologies Corporation (NASDAQ: DVAX) Gilead Sciences, Inc. (NASDAQ: GILD) Harvard Bioscience, Inc. (NASDAQ: HBIO) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Innoviva, Inc. (NASDAQ: INVA) Johnson & Johnson (NYSE: JNJ) Sesen Bio, Inc. (NASDAQ: SESN) Tenaya Therapeutics, Inc. (NASDAQ: TNYA) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 12) ABVC BioPharma, Inc. (NASDAQ: ABVC) (announced its second-quarter results) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Achilles Therapeutics plc (NASDAQ: ACHL) Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) Akero Therapeutics, Inc. (NASDAQ: AKRO) Allogene Therapeutics, Inc. (NASDAQ: ALLO) Alzamend Neuro, Inc. (NASDAQ: ALZN) Aprea Therapeutics, Inc. (NASDAQ: APRE) (announced that FDA imposed clinical hold on lymphoid malignancy study) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) (announced second-quarter results) Atai Life Sciences N.V. (NASDAQ: ATAI) (announced setting up of a subsidiary for studying Salvinorin A for mental health disorders) Axsome Therapeutics, Inc. (NASDAQ: AXSM) Aytu Biopharma, Inc. (NASDAQ: AYTU) Baudax Bio, Inc. (NASDAQ: BXRX) Baxter International Inc. (NYSE: BAX) Biodesix, Inc. (NASDAQ: BDSX) Biomea Fusion, Inc. (NASDAQ: BMEA) Cellectar Biosciences, Inc. (NASDAQ: CLRB) Celularity Inc. (NASDAQ: CELU) Codex DNA, Inc. (NASDAQ: DNAY) CytomX Therapeutics, Inc. (NASDAQ: CTMX) DiaMedica Therapeutics Inc. (NASDAQ: DMAC) (reacted to its second-quarter results) Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) Edgewise Therapeutics, Inc. (NASDAQ: EWTX) Ensysce Biosciences, Inc. (NASDAQ: ENSC) Epizyme, Inc. (NASDAQ: EPZM) Exicure, Inc. (NASDAQ: XCUR) (announced its second-quarter results) EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) FibroGen, Inc. (NASDAQ: FGEN) Flexion Therapeutics, Inc. (NASDAQ: FLXN) Grifols, S.A. (NASDAQ: GRFS) Heron Therapeutics, Inc. (NASDAQ: HRTX) HOOKIPA Pharma Inc. (NASDAQ: HOOK) (reacted to its second-quarter result) Hoth Therapeutics, Inc. (NASDAQ: HOTH) IMARA Inc. (NASDAQ: IMRA) IN8bio, Inc. (NASDAQ: INAB) Incyte Corporation (NASDAQ: INCY) Inhibikase Therapeutics, Inc. (NASDAQ: IKT) iRhythm Technologies, Inc. (NASDAQ: IRTC) Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) Kronos Bio, Inc. (NASDAQ: KRON) Lava Therapeutics B.V. (NASDAQ: LVTX) Liminal BioSciences Inc. (NASDAQ: LMNL) Lumos Pharma, Inc. (NASDAQ: LUMO) MediciNova, Inc. (NASDAQ: MNOV) Moleculin Biotech, Inc. (NASDAQ: MBRX) (reacted to its second-quarter ...

    Benzinga
Page data last updated 07/23/2025 20:47:02 UTC